Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2016
Event: Entry into a Material Definitive Agreement and unregistered sale of equity securities.
Key Financial Metrics and Transaction Details
This filing reports a capital raise rather than operational financial results. Key transaction metrics include:
- Proceeds Raised: $1,529,750
- Shares Issued: 25,495,835 shares of Common Stock
- Warrants Issued: 25,495,835 Class L Warrants
- Warrant Exercise Price: $0.08 per share
- Warrant Expiration: March 17, 2019
- Use of Proceeds: Working capital and general corporate purposes
Note: The filing does not provide current revenue, profit, cash flow, margins, or debt levels. Investors should refer to the Company's most recent Form 10-K for operational financial data.
Material Changes and Transaction Structure
The Company completed an offering of securities to accredited investors pursuant to an effective Form S-1 registration statement (No. 333-208676). The transaction closed on March 11, 2016. The issuance was exempt from registration under Section 4(a)(2) of the Securities Act and Regulation D. No general solicitation or advertising was utilized.
Guidance, Risks, and Unusual Items
- Forward-Looking Statements: The filing contains forward-looking statements regarding projected growth, future revenue, and anticipated improvements in earnings. These are subject to risks and uncertainties detailed in the Company's Form 10-K.
- Related Party Transaction: Michael N. Nemelka, the brother of a board member and an existing shareholder, participated as a purchaser in the offering.
- Regulatory Disclosure: A press release announcing the closing was issued on March 14, 2016, under Regulation FD.
Investor Verification Checklist
- Verify the dilution impact of issuing 25,495,835 new shares and an equal number of warrants.
- Review the Company's most recent Form 10-K to assess current liquidity and working capital needs prior to this infusion.
- Confirm the terms of the Class L Warrants, specifically the $0.08 exercise price and 2019 expiration date.
- Assess the extent of related party involvement in the capital raise.